PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32860126-4 2021 RESULTS: We first showed that HQ and IQ significantly enhanced the anticancer effect of CDDP by upregulating p53- and p21-associated pathways, while tended to attenuate CDDP-induced fat loss in tumor-bearing nude mice. Cisplatin 88-92 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 118-121 31889899-0 2019 Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cisplatin 70-79 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 122-128 32843706-4 2020 Here, we show that cisplatin induces senescent-like neuronal cells in primary culture and in mouse dorsal root ganglia (DRG), as determined by the characteristic senescence markers including senescence-associated beta-galactosidase, accumulation of cytosolic p16INK4A and HMGB1, as well as increased expression of p16Ink4a, p21, and MMP-9. Cisplatin 19-28 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 324-327 32597980-9 2021 CONCLUSIONS: In this study, we determined that after cisplatin-induced DNA damage, p21 appears as the most relevant downstream factor of the DDR in DRG sensory neurons in vivo, which survive in a non-functional senescence-like state. Cisplatin 53-62 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 83-86 31889899-10 2019 Results: CDKN1A was highly expressed in cisplatin-sensitive OC cell lines, and silencing CDKN1A significantly promoted proliferation and cell cycle entry but decreased apoptosis in cisplatin-sensitive OC cells. Cisplatin 40-49 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 9-15 31889899-10 2019 Results: CDKN1A was highly expressed in cisplatin-sensitive OC cell lines, and silencing CDKN1A significantly promoted proliferation and cell cycle entry but decreased apoptosis in cisplatin-sensitive OC cells. Cisplatin 40-49 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 89-95 31889899-10 2019 Results: CDKN1A was highly expressed in cisplatin-sensitive OC cell lines, and silencing CDKN1A significantly promoted proliferation and cell cycle entry but decreased apoptosis in cisplatin-sensitive OC cells. Cisplatin 181-190 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 89-95 31078568-8 2019 SRI110 co-treatment reversed the cisplatin-induced changes in the expression levels of Bcl2l1, Ccnd1, Jak2, Jak3, and Src and significantly attenuated the changes in the expression levels of Cdkn1a, Egfr, Fas, Il6st, Jak1, Stat3, and Tyk2. Cisplatin 33-42 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 191-197 26725321-7 2016 We observed elevated p21 expression also in the regenerating livers of SOCS1-deficient mice and in cisplatin-treated Socs1-null hepatocytes, wherein the p21 protein showed increased stability. Cisplatin 99-108 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 21-24 29753739-5 2018 Moreover, cisplatin circadian time-dependently induced p21 expression in the liver, heart and kidney, with the highest increase during the dark phase. Cisplatin 10-19 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 55-58 28746345-5 2017 In A549 cells, cisplatin exposure led to a significantly higher expression of genes coding for proteins mediating G2/M arrest and apoptosis (mouse double minute 2 homolog (MDM2), xeroderma pigmentosum complementation group C (XPC), stress inducible protein (SIP) and p21) compared to resistant cells. Cisplatin 15-24 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 267-270 29449532-5 2018 CDDP treatment induced melanoma A375 cells into senescence through the sequential activation of the DNA damage response and the P53/P21 pathway. Cisplatin 0-4 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 132-135 27604276-6 2016 This model was used to determine the capacity of a number of DNA-damaging agents, including IR, cisplatin, and etoposide to induce p21 expression in normal tissues. Cisplatin 96-105 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 131-134 19428948-11 2009 As expected, the genotoxins B[a]P and cis-platin led to p53 accumulation and induction of its target p21. Cisplatin 38-48 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 101-104 27721894-3 2016 We found that CDDP, when administered with FGS, significantly decreased the viability and increased the apoptosis and cell cycle arrest of Lewis lung carcinoma (LLC) cells, which were associated with the increase of p21 and decreases of cyclin D1 and CDK4. Cisplatin 14-18 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 216-219 27721894-4 2016 Concordantly, when combined with FGS, CDDP significantly reduced the volume and weight of tumors derived from LLC subcutaneously injected into C57BL/6 mice, with concomitant increases of phosphor-p53 and p21 in tumor tissue. Cisplatin 38-42 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 204-207 24933647-9 2014 Furthermore, UA17/cisplatin combination exhibited increase of p21, cyclin E, and p-p53 level, and decrease of p27 and cyclin D1 proteins, and slightly diminishing the level of CDK2. Cisplatin 18-27 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 62-65 24823295-10 2014 Furthermore, the mRNA levels of myostatin and p21 were significantly upregulated by the administration of cisplatin, compared to DR. On the other hand, the phosphorylation of Akt and FOXO3a, which leads to the blockade of the upregulation of MuRF1 and MAFbx, was significantly and dramatically decreased by cisplatin. Cisplatin 106-115 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 46-49 24823295-10 2014 Furthermore, the mRNA levels of myostatin and p21 were significantly upregulated by the administration of cisplatin, compared to DR. On the other hand, the phosphorylation of Akt and FOXO3a, which leads to the blockade of the upregulation of MuRF1 and MAFbx, was significantly and dramatically decreased by cisplatin. Cisplatin 307-316 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 46-49 22674879-6 2013 Increased expression of p21 and Bcl-2 as well as decreased expression of Bax were observed after cisplatin treatment by Western blotting. Cisplatin 97-106 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 24-27 15113856-7 2004 p21 expression was high and remained unchanged in cisplatin treated wt cells, although it was reduced in the absence of p53. Cisplatin 50-59 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 0-3 17158520-0 2007 Cisplatin-DNA damage in p21WAF1/Cip1 deficient mouse keratinocytes exposed to cisplatin. Cisplatin 0-9 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 32-36 17158520-5 2007 At 48 h of cisplatin exposure p21(WAF1/Cip1) mRNA expression was 2-fold higher in the (+/+) cells, compared to the (+/-) cells. Cisplatin 11-20 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 30-33 17158520-5 2007 At 48 h of cisplatin exposure p21(WAF1/Cip1) mRNA expression was 2-fold higher in the (+/+) cells, compared to the (+/-) cells. Cisplatin 11-20 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 34-38 17158520-5 2007 At 48 h of cisplatin exposure p21(WAF1/Cip1) mRNA expression was 2-fold higher in the (+/+) cells, compared to the (+/-) cells. Cisplatin 11-20 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 39-43 17158520-6 2007 At 24 h, the % of cells in S-phase in cisplatin-exposed cultures, compared to unexposed cultures, was decreased by 51, 40 and 11% in p21(WAF1/Cip1) (+/+), (+/-) and (-/-) cells, respectively (P = 0.04, ANOVA). Cisplatin 38-47 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 133-136 17158520-6 2007 At 24 h, the % of cells in S-phase in cisplatin-exposed cultures, compared to unexposed cultures, was decreased by 51, 40 and 11% in p21(WAF1/Cip1) (+/+), (+/-) and (-/-) cells, respectively (P = 0.04, ANOVA). Cisplatin 38-47 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 137-141 17158520-6 2007 At 24 h, the % of cells in S-phase in cisplatin-exposed cultures, compared to unexposed cultures, was decreased by 51, 40 and 11% in p21(WAF1/Cip1) (+/+), (+/-) and (-/-) cells, respectively (P = 0.04, ANOVA). Cisplatin 38-47 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 142-146 15547703-0 2004 Induction of p21 and nuclear accumulation of TAp73alpha and c-abl during apoptosis of cisplatin-treated primary pancreatic acinar cells. Cisplatin 86-95 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 13-16 12492115-8 2002 Cisplatin induced p53 and its downstream targets, p21(Cip1) (p21) and Bax, in both cell populations. Cisplatin 0-9 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 50-58 12965891-8 2004 Using several cell cycle inhibitors, including a p21 adenovirus, and the drugs roscovitine and olomoucine, we have been able to completely protect a mouse kidney proximal tubule cell culture from cisplatin-induced apoptosis. Cisplatin 196-205 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 49-52 12746256-0 2003 Lack of a functional p21WAF1/CIP1 gene accelerates caspase-independent apoptosis induced by cisplatin in renal cells. Cisplatin 92-101 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 21-33 12746256-1 2003 The lack of cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21) in mice increases renal proximal tubular cell death and enhances sensitivity to acute renal failure produced by the chemotherapeutic agent cisplatin. Cisplatin 204-213 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 46-58 12746256-1 2003 The lack of cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21) in mice increases renal proximal tubular cell death and enhances sensitivity to acute renal failure produced by the chemotherapeutic agent cisplatin. Cisplatin 204-213 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 46-49 12746256-3 2003 Cisplatin (15 microM) activated caspase-3 but not caspase-8 or caspase-9 and produced phosphatidylserine externalization, chromatin condensation, and nuclear fragmentation in wild-type [p21(+/+)] MPTC. Cisplatin 0-9 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 186-189 12746256-4 2003 Caspase-3 activation and apoptosis were accelerated in cisplatin-treated MPTC lacking p21 [p21(-/-) MPTC]. Cisplatin 55-64 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 86-89 12746256-4 2003 Caspase-3 activation and apoptosis were accelerated in cisplatin-treated MPTC lacking p21 [p21(-/-) MPTC]. Cisplatin 55-64 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 91-94 12746256-9 2003 We conclude that 1) in the presence of p21, cisplatin activates caspase-3 through a mechanism independent of caspase-8 or caspase-9; 2) in the absence of p21, caspase-9 activation precedes caspase-3 activation; 3) the lack of p21 accelerates caspase-3 activation and cisplatin-induced MPTC apoptosis; and 4) MPTC apoptosis is caspase independent in the presence of p21 but partially dependent on caspases in the absence of p21. Cisplatin 44-53 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 39-42 12217873-3 2002 We found that after acute renal failure induced by either cisplatin injection or renal ischemia, induction of the p21 cyclin-dependent kinase (cdk) inhibitor is protective. Cisplatin 58-67 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 114-117 12492115-8 2002 Cisplatin induced p53 and its downstream targets, p21(Cip1) (p21) and Bax, in both cell populations. Cisplatin 0-9 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 50-53 9600935-6 1998 In the latter cells, cisplatin exposure caused prolonged cell cycle arrest accompanied by induction of the p21 gene. Cisplatin 21-30 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 107-110 11737590-3 2001 The p21 mRNA is induced in murine kidney after several types of acute renal failure, including cisplatin administration, ischemia-reperfusion, and ureteral obstruction. Cisplatin 95-104 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 4-7 11737590-4 2001 We reported that after cisplatin injection, mice with a p21 gene deletion developed much more severe renal damage than wild-type mice. Cisplatin 23-32 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 56-59 9466972-0 1998 Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. Cisplatin 76-85 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 26-30 9466972-3 1998 The function(s) in the kidney of p21 induction in cisplatin-induced acute renal failure was studied with mice that are homozygous for a p21 gene deletion. Cisplatin 50-59 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 33-36 9466972-5 1998 Therefore, the induction of p21 after cisplatin administration is a protective event for kidney cells. Cisplatin 38-47 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 28-31 9466972-8 1998 We propose that p21 protects kidneys damaged by cisplatin by preventing DNA-damaged cells from entering the cell-cycle, which would otherwise result in death from either apoptosis or necrosis. Cisplatin 48-57 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 16-19 8997395-1 1996 In three different models of acute renal failure (ischemia, ureteral obstruction, and cisplatin administration), the p21WAF1/CIP1/SDI1 gene, the protein product of which is associated with cell-cycle interruption, terminal differentiation, and cellular senescence, was activated in murine kidney cells. Cisplatin 86-95 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 125-129 9466972-0 1998 Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. Cisplatin 76-85 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 21-25 8997395-1 1996 In three different models of acute renal failure (ischemia, ureteral obstruction, and cisplatin administration), the p21WAF1/CIP1/SDI1 gene, the protein product of which is associated with cell-cycle interruption, terminal differentiation, and cellular senescence, was activated in murine kidney cells. Cisplatin 86-95 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 130-134 8997395-5 1996 We also present evidence that, in the cisplatin model, both p53-independent and p53-dependent induction of p21 mRNA occur simultaneously. Cisplatin 38-47 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 107-110